Gyermekkori daganatok: vizsgálatok itt: Németország
144 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 2. fázisNot yet taking people in NémetországACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
- Where
- Heidelberg
- Életkor
- 12 hónap to 39 év
- People
- 60 worldwide
- Run by
- Nationwide Children's Hospital
See details and how to joinNCT06838676 - 1/2. fázisTaking peopleA Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination with Chemoimmunotherapy in Pediatric and Young Adult Participants with Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
- Where
- Muenster
- Életkor
- Up to 17 év
- People
- 37 worldwide
- Run by
- F. Hoffmann-La Roche AG
See details and how to join2023-504264-41-00 - No phaseTaking peopleShadow-Mode Evaluation of an AI Assistant for Multidisciplinary Tumor Boards
- Where
- Munich
- People
- 450
- Run by
- Technical University of Munich
See details and how to joinNCT07939139 - 1/2. fázisTaking peopleA Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Where
- Muenster, Tuebingen
- Életkor
- 6 hónap to 17 év
- People
- 370 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT02332668 · EU 2022-501257-36-00 - 2. fázisTaking peopleBelzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Where
- Berlin, Düsseldorf, Freiburg im Breisgau, München, Würzburg
- Életkor
- 12 év and over
- People
- 355 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00 - No phaseNot yet taking people in NémetországHIIT-based Exercise Intervention for Improvement of Immunomodulatory, Cardiopulmonary, and Psychosocial Parameters During Maintenance Therapy of Paediatric Acute Lymphoblastic Leukaemia (HEALL)
- Where
- Erlangen
- Életkor
- 6 év to 10 év
- People
- 108
- Run by
- University of Erlangen-Nürnberg Medical School
See details and how to joinNCT07936786 - 3. fázisNot yet taking people in NémetországA Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
- Where
- Muenster
- Életkor
- 1 év to 64 év
- People
- 130 worldwide
- Run by
- Memorial Sloan Kettering Cancer Center
See details and how to joinNCT07223021 · EU 2025-523096-34-00 - 1. fázisTaking peopleA phase I safety, dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers
- Where
- Erlangen, Essen, Muenster, Tuebingen
- People
- 48
- Run by
- Universitaet Muenster
See details and how to join2022-501725-21-00 - 4. fázisFut, nem toborozDabrafenib and/or Trametinib Rollover Study
- Where
- Augsburg, Essen, Hamburg, Heidelberg, Mannheim
- Életkor
- 18 év to 100 év
- People
- 100 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00 - 3. fázisTaking peopleStudy of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
- Where
- Berlin, Bonn, Essen, Hamburg, Leipzig
- Életkor
- 15 év and over
- People
- 800 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06079671 · EU 2023-504374-38-00 - 2. fázisTaking peopleStudy to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
- Where
- Erlangen, Frankfurt am Main, Hamburg
- Életkor
- 1 év to 18 év
- People
- 50 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07354074 - 4. fázisTaking peopleAsciminib Roll-over Study
- Where
- Aachen, Augsburg, Bad Saarow, Berlin, Bonn, Chemnitz, Dresden, Erlangen, Frankfurt Am Main, Freiburg im Breisgau, Halle (Saale), Hamburg, Jena, Kiel, Leipzig, Mannheim, Marburg, Muenchen, Munich, Regensburg, Ulm, Wuerzburg
- Életkor
- 7 év to 100 év
- People
- 347 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00 - 1. fázisNot yet taking people in NémetországA Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
- Where
- Berlin, Munich, Ulm
- People
- 225 worldwide
- Run by
- Janssen Cilag International
See details and how to join2026-525234-39-00 - 1/2. fázisTaking peopleA Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Where
- Cologne, Frankfurt Am Main, Grosshansdorf, Heidelberg
- Életkor
- 12 év and over
- People
- 840 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00 - 1. fázisTaking peopleA Phase I Dose Finding Study of MB-CART2219.1
- Where
- Tuebingen
- Életkor
- 12 év to 75 év
- People
- 36
- Run by
- University Hospital Tuebingen
See details and how to joinNCT07108868 · EU 2024-516838-35-00 - 1/2. fázisTaking peopleA Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
- Where
- Münster
- Életkor
- 6 hónap to 30 év
- People
- 65 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05533775 - No phaseTaking peopleIMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCE
- Where
- Aschaffenburg, Bergisch Gladbach, Erlangen, Esslingen am Neckar, Itzehoe, Kulmbach, Lübeck, Wilhelmshaven
- People
- 257
- Run by
- Institut fuer Frauengesundheit
See details and how to joinNCT07521202 - 1. fázisNot yet taking people in NémetországGD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors
- Where
- Münster
- Életkor
- 1 év to 25 év
- People
- 30
- Run by
- Universität Münster
See details and how to joinNCT07897968 - 2/3. fázisTaking peopleLong-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- Where
- Berlin, Chemnitz, Cologne, Dresden, Duesseldorf, Erlangen, Essen, Frankfurt Am Main, Hamburg, Hanover, Heidelberg, Karlsruhe, Magdeburg, Munich, Regensburg, Tuebingen, Ulm, Wuerzburg
- People
- 1541 worldwide
- Run by
- Celgene
See details and how to joinNCT03435796 · EU 2023-504201-36-00 - No phaseNot yet taking people in NémetországAssessment of Intelligent Algorithms for Detection, Diagnosis and Risk Stratification of Tumors of the Kidney and Prostate
- Where
- Berlin, München
- People
- 50 worldwide
- Run by
- Aristotle University Of Thessaloniki
See details and how to joinNCT07888322 - 1/2. fázisTaking peopleSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Where
- Berlin, Cologne, Giessen, Muenster, Tuebingen
- Életkor
- 6 hónap to 25 év
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00 - 1/2. fázisBefejeződöttA Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
- Where
- Berlin, Cologne, Muenster
- Életkor
- 1 hónap to 17 év
- People
- 134 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07630974 · EU 2025-522339-32-00 - No phaseTaking peopleMore Than Just X-Rays - Imaging of Chemotherapy-induced Morphological and Functional Cardiovascular and Lung Changes After Childhood ALL and Other Cancers - a Monocentric Late Effects Study (MaximALL)
- Where
- Erlangen
- Életkor
- 3 év and over
- People
- 180
- Run by
- University of Erlangen-Nürnberg Medical School
See details and how to joinNCT07705178 - No phaseTaking peopleMet Non Small Cell Cancer Registry (MOMENT)
- Where
- Chemnitz, Großhansdorf, Heidelberg, Löwenstein
- People
- 700 worldwide
- Run by
- EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT05376891 - No phaseTaking peopleMaster Framework For Relapse or Refractory Acute Myeloid Leukemia
- Where
- Aachen, Greifswald, Halle, Rostock
- Életkor
- 6 év and over
- People
- 4000 worldwide
- Run by
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
See details and how to joinNCT06459024